In this review:
This conference attracted around 6000 delegates from across the globe. Among them was Dr Rupert Handy, who independently selected and reviewed a number of presentations, which he considers relevant to current clinical practice. This review begins with important observations from the recently released START and TEMPRANO trials, which showed that starting treatment at a CD4 cell count >500 cells/mm3 resulted in less serious illness and AIDSrelated deaths than if treatment was deferred.
Please login below to download this issue (PDF)